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Abstract
Background: The activity of macrophages is implicated in the progression of retinal pathologies such as atrophic
age-related macular degeneration (AMD), where they accumulate among the photoreceptor layer and subretinal
space. This process is aided by the local expression of chemokines, which furnish these cells with directional cues
that augment their migration to areas of retinal injury. While these qualities make chemokines a potential
therapeutic target in curtailing damaging retinal inflammation, their wide variety and signalling redundancy pose
challenges in broadly modulating their activity. Here, we examine the efficacy of the broad-spectrum chemokine
inhibitor NR58-3.14.3—a suppressor of Ccl- and Cxcl- chemokine pathways—in suppressing macrophage activity
and photoreceptor death, using a light-induced model of outer retinal atrophy and inflammation.
Methods: Photo-oxidative damage was induced in SD rats via exposure to 1000 lux of light for 24 h, after which
animals were euthanized at 0- or 7-day post-exposure time points. Prior to damage, NR58-3.14.3 was injected
intravitreally. Retinas were harvested and evaluated for the effect of NR58-3.14.3 on subretinal macrophage
accumulation and cytokine expression profile, as well as photoreceptor degeneration.
Results: We report that intravitreal administration of NR58-3.14.3 reduces the accumulation of macrophages in the
outer retina following exposure to light damage, at both 0- and 7-day post-exposure time points. Injection of
NR58-3.14.3 also reduced the up-regulation of inflammatory markers including of Il6, Ccl3, and Ccl4 in infiltrating
macrophages, which are promoters of their pathogenic activity in the retina. Finally, NR58-3.14.3-injected retinas
displayed markedly reduced photoreceptor death following light damage, at both 0 and 7 days post-exposure.
Conclusions: Our findings indicate that NR58-3.14.3 is effective in inhibiting subretinal macrophage accumulation
in light-induced retinal degeneration and illustrate the potential of broad-spectrum chemokine inhibitors as novel
therapeutic agents in thwarting retinal inflammation. Although broad-spectrum chemokine inhibitors may not be
appropriate for all retinal inflammatory conditions, our results suggest that they may be beneficial for retinal
dystrophies in which chemokine expression and subretinal macrophage accumulation are implicated, such as
advanced AMD.
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Background
Age-related macular degeneration (AMD) is the leading
cause of irreversible blindness among those aged over 65
in industrialised nations [1]. It is a progressive retinop-
athy that affects the photoreceptor population, retinal
pigment epithelium (RPE), and Bruch’s membrane, and
the choroid at various stages of the disease. The
advanced stages of AMD are classified into two forms:
exudative ‘wet’ AMD, induced by sudden choroidal neo-
vascularisation (CNV), and geographic atrophy (GA)
marked by a progressive expanding lesion of the RPE,
photoreceptors, and choriocapillaris. While AMD has a
complex aetiology involving multiple lifestyle and genetic
risk factors, the significance of immunological processes
has emerged slowly [2–7]. The relatively recent confirm-
ation in genome-wide association studies (GWAS) of the
importance of the complement system and macrophages
has placed inflammation among the forefront of factors
influencing both the onset and progression of AMD [8, 9].
The accumulation and activation of macrophages within
the retinal tissues is a prominent feature of most retinopa-
thies and is well documented in all forms of AMD. Micro-
glial cells are the resident macrophages of the retina that
are derived from embryonic yolk sac progenitors during
development [10, 11], while non-resident bone marrow-
derived macrophages may be recruited into the retina from
the vasculature in pathology [12, 13]. In AMD lesions,
macrophages form large aggregations in the photoreceptor
layer, subretinal space, and RPE [4, 6, 7, 14–17], which are
typically free of these leukocytes in healthy individuals [18].
Despite having some beneficial properties [19], excessive
accumulation of these cells is implicated in degeneration in
animal models of AMD, retinal detachment [20], diabetic
retinopathy [21–23], and glaucoma [24, 25].
Chemokines are key regulators of macrophage activa-
tion and accumulation in AMD [26, 27], as well as de-
generations associated with retinal detachment [20] and
diabetic retinopathy [23]. The chemokine family com-
prises more than 50 molecules and associated receptors
that activate and recruit leukocytes to sites of damage.
Transcriptome-wide analysis of AMD donor retinas re-
ports that the leukocyte chemoattractants Ccl2, Cxcl1,
Cxcl10, and Cxcl11 are up-regulated in all forms of the
disease [28]. Moreover, intraocular Ccl2 protein levels
are increased in patients with CNV or GA [16, 29, 30],
and infiltrating microglia/monocytes in retinas with GA
express the cognate Ccl2 receptor, Ccr2 [16]. Chemokine
signalling is implicated in exacerbating the accumulation
of macrophages and photoreceptor death in a range of
animal models that demonstrate some features in com-
mon with AMD, including laser-induced CNV [31],
photo-oxidative stress [16, 32, 33], Abca4−/−Rdh8−/−
mice [34], and carboxyethylpyrrole (CEP)-immunised
mice [35].
While these findings underscore the importance of
chemokines in shaping inflammation in the retina,
therapeutic blockade of individual chemokine ligands/
receptors may have limited efficacy due to chemokine
receptor redundancy, and the tendency toward compen-
satory increases in expression of other chemokine family
members [34, 36]. Broad-spectrum chemokine inhibitors
(BSCIs) are a class of chemokine modulators with the
ability to inhibit signal transduction of a broad swathe of
chemokine receptors [37]. Among these, NR58-3.14.3 is a
robust cyclic peptide that specifically inhibits chemokine-
mediated migration of macrophages by blocking the sig-
nalling of Ccl- and Cxcl- pathways [37]. NR58-3.14.3 has
been shown to effectively inhibit macrophage accumula-
tion and ameliorate pathology in lung ischemia [38], oblit-
erative bronchiolitis [39], skin inflammation [37], and
atherosclerotic plaques [40].
To our knowledge, there are no studies which have ex-
plored the potential of BSCIs in retinal degeneration
models. Here, we investigate the effect of NR58-3.14.3 in
modulation of the accumulation of macrophages in the
outer retina, using a light-induced model of oxidative
stress and retinal inflammation. While acute exposure to
light damage does not induce some of the classical fea-
tures of AMD (including drusen and CNV), it induces
focal and progressive atrophy of the outer retina and
models very effectively the accumulation of subretinal
macrophages and up-regulation of chemokines Ccl2,
Cxcl1, Cxcl10, and Cxcl11 [41]. Furthermore, we have
shown that the degenerative changes associated with
light damage closely mimic naturally occurring degen-
erative changes in the ageing rat retina [42].
In the current study, we show that intravitreal delivery
of NR58-3.14.3 is safely tolerated in experimental ani-
mals, is long-lasting in the retinal environment, sup-
presses macrophage accumulation in the outer retina,
and reduces retinal pathology following light damage.
Additionally, we demonstrate that NR58-3.14.3 reduces
the expression of pro-inflammatory factors Il6, Ccl3, and
Ccl4 by macrophages, which are implicated in promot-
ing their deleterious activity in retinal dystrophy. These
data provide proof-of-principle support of the value of
BSCIs in thwarting deleterious macrophage activity in
retinal degeneration.
Methods
Animal handling and rearing
All experiments were in accordance with the ARVO
Statement for Use of Animals in Ophthalmic and Vision
Research and with approval from the ANU Animal Ex-
perimentation Ethics Committee (Ethics ID: A2014/56).
Adult Sprague-Dawley (SD) rats were utilised in all
experiments, which were born and reared under dim-
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light conditions (5 lux) and aged between 90 and 120
post-natal days at the time of use.
Preparation of NR58-3.14.3 and intravitreal injections
Animals were anaesthetised with an intraperitoneal in-
jection of ketamine (100 mg/kg; Troy Laboratories,
NSW, Australia) and Xylazil (12 mg/kg; Troy Laborator-
ies, NSW, Australia). Intravitreal injections of consisting
of 3 μL were conducted as described previously [32]; this
route was preferred over systemic administration as it
minimises the potential for off-target effects which may
cofound the data. The 3-uL injection volume was chosen
as it offers good reproducibility, minimal disturbance in
vitreal volume, and negligible cataract formation [43].
The broad-spectrum chemokine inhibitor (BSCI) NR58-
3.14.3 (Auspep, VIC, Australia) was reconstituted in
endotoxin-free 0.1 M PBS to a final concentration of
66.7 μg/μl. In the treatment group, 3 μl of NR58-3.14.3
in PBS was intravitreally injected into both eyes of each
animal, so that 200 μg of NR58-3.14.3 was delivered to
each eye. The control group received an injection of 3 μl
PBS vehicle in each eye. Following intravitreal injections,
the animals were monitored closely throughout the time
course of experiments. As expected, no incidences of cata-
ract formation or other abnormalities were observed.
Light damage
Immediately after administering intravitreal injections,
animals were exposed to 1000 lux light for a period of
24 h, as described previously [44]. During light damage,
animals were placed into transparent Perspex open-top
cages under a light source (COLDF2, 2 × 36 W, IHF,
Thorn Lighting, Australia) with access to food and water
ad libitum. After light damage, animals were either
euthanized for tissue collection (0 day time point) or
were placed into recovery under dim-light conditions
(5 lux) for 7 days.
Retinal localisation of injected NR58-3.14.3 via fluorescein
The fluorescein-labelled NR58-3.14.3 was prepared using
an NHS-Fluorescein Antibody Labelling Kit (Pierce,
Thermo Fisher Scientific, MA, USA), applied according
to the manufacturer’s protocol. In brief, the NR58-3.14.3
was reconstituted in endotoxin-free PBS to a concentra-
tion of 1 mg/ml. The NR58-3.14.3 was then incubated
with the NHS-Fluorescein for 1 h at room temperature,
before being purified through a column to remove ex-
cess dye from the final product. The fluorescein-NR58-
3.14.3 was stored at 4 °C. Using the intravitreal proced-
ure described earlier, each animal was injected with 3 μl
fluorescein-NR58-3.14.3 in one eye only; the contralat-
eral eye was used as either a fluorescein-only-injected
control, or a non-injected control. Following the injec-
tion, animals were placed under dim-light conditions to
recover. Both eyes of each animal were collected for cryo-
sectioning at several times after the injection (20 min, 3 h,
24 h, and 7 days). The levels of fluorescein-NR58-3.14.3 in
injected retinas were measured on cryosections. The fluor-
escence was visualised with a laser-scanning A1+ confocal
microscope (Nikon, Tokyo, Japan), and images were
acquired at consistent regions using the NIS-Elements AR
software (Nikon, Tokyo, Japan). From these images, fluor-
escence intensity was quantified with ImageJ software
(NIH, MD, USA), using integrated density for a fixed area.
Tissue collection and processing of whole retinas
Animals were euthanized using an overdose of barbitur-
ate, which was administered via intraperitoneal injection
(Valabarb; Virbac, NSW, Australia). The left eye from
each animal was marked for orientation then enucleated
for cryosectioning, while the retina from the right eye
was excised through a corneal incision for RNA extrac-
tion. Both cryosectioning and RNA extraction of the
excised retinas were performed according to our previ-
ous methodology [45].
Fluorescence-activated cell sorting (FACS) of retinal
macrophages
Rats in each treatment group were euthanized immedi-
ately after light damage (0 day) using barbiturate over-
dose as previously described. Retinas from both eyes
were promptly removed through a corneal incision. Ret-
inas from each animal were pooled and immediately
placed in chilled Hank’s balanced salt solution (HBSS)
and then subjected to light mechanical separation using
a razor blade. Samples were transferred into a 0.2 %
papain digestion cocktail as described in our previous
protocol [41], with minor modifications. Samples were
incubated at 37 °C for 7 min then 8 °C for 30 min. After
neutralisation and resuspension, the resulting homogen-
ate was incubated in staining buffer containing a CD11b
antibody conjugated to Alexa 647 (Biolegend, San Diego,
CA, USA) for 30 min at 4 °C, and then washed in HBSS
and resuspended in staining buffer. The resultant CD11b-
stained samples were run through a fluorescence-activated
cell sorter (FACS) (BD FACSAria II; BD Biosciences,
Franklin Lakes, NJ, USA). The isolated CD11b+ macro-
phages were collected in staining buffer and kept chilled
on ice until RNA extraction could be commenced. RNA
extraction was conducted via a protocol we have previously
established [41]. Isolated total RNA was analysed for quan-
tity and purity with a ND-1000 spectrophotometer (Nano-
drop Technologies, Wilmington, DE, USA).
TUNEL assay and quantification of photoreceptor survival
To quantify levels of photoreceptor cell death in the ret-
ina, retinal cryosections were stained for apoptosis using
a terminal deoxynucleotidyl transferase dUTP nick end
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labelling (TUNEL) kit (Roche Diagnostics, NSW,
Australia) as previously described [46, 47]. TUNEL+ cells
in the ONL were counted throughout the full length of
each retinal section along the para-sagittal plane (supero-
inferior) and also included the optic nerve for consistency.
These counts were subsequently averaged for each experi-
mental group. To quantify photoreceptor survival, sec-
tions were stained with bisbenzimide (Sigma-Aldrich Co.,
MO, USA) and the number of rows of photoreceptor cell
bodies in the ONL were counted. Five counts were made
for each retinal section and then were averaged for each
experimental group.
Immunohistochemistry
Cryosections were used for immunohistochemical ana-
lysis, using antibodies against IBA1 (1:500, Wako, Osaka,
Japan) and GFAP (1:500, Dako, Agilent Technologies, CA,
USA) as described in our previous study, with minor mod-
ifications [41, 44]. Fluorescence in retinal sections was
captured with a laser-scanning A1+ confocal microscope
(Nikon, Tokyo, Japan). Images panels were analysed and
assembled using ImageJ (NIH, MD, USA) and Photoshop
CS6 software (Adobe Systems, CA, USA).
Quantification of infiltrating macrophages
Macrophage counts were performed on sections immuno-
labelled with the IBA1 marker, a label for retinal microglia
and macrophages. Counts of IBA1+ cells were carried out
along the full length of retinal sections cut in the para-
sagittal plane (supero-inferior) within the vertical merid-
ian, and each section also included the optic nerve to
ensure consistency. Counts were made of all IBA1+ cells
throughout the retina, which were split into two groups:
the inner retina (ILM-OPL) and the outer retina (ONL-
RPE) where activated macrophages are known to aggre-
gate during retinal degeneration [19, 20, 48].
Polymerase chain reaction
cDNA was prepared from 1 μg of RNA of each sample
using a Tetro cDNA Synthesis Kit (Bioline Reagents,
London, UK). The quantitative real-time polymerase
chain reactions (qPCRs) were conducted using Taqman
hydrolysis probes (Table 1) and Taqman Gene Expres-
sion Master Mix (Applied Biosystems, Life Technologies,
CA, USA). These were applied following the manufac-
turer’s instructions and run on a QuantStudio Flex 12K
instrument (Applied Biosystems), at the Biomolecular
Resource Facility, JCSMR, ANU. Data analysis was per-
formed using Expression Suite v1.0.3 software (Life
Technologies, CA, USA); the fold change was deter-
mined for each gene and sample using the comparative
cycle threshold (Ct) method (ΔΔCt). All data was nor-
malised to the GAPDH reference gene, which does not
change in expression over the course of retinal light
damage [49, 50]. ACTB was utilised as an additional ref-
erence gene in qPCRs involving the CD11b+ isolates.
Standard PCR was performed on RNA samples puri-
fied from FACS-isolated CD11b+ macrophages, using
primers specific to chemokine receptor genes (Ccr1,
Ccr2, Ccr5, Cxcr3) which are detailed in our previous in-
vestigation [41]. First-strand cDNA synthesis was per-
formed from 50 ng of RNA using the Tetro cDNA
Synthesis Kit (Bioline), and standard PCR was then per-
formed using MyTaq DNA polymerase (Bioline); nega-
tive controls had cDNA omitted from the reaction
cocktail. The presence of PCR product and specificity of
the reaction were assessed by gel electrophoresis.
In situ hybridisation
Ccl3 was cloned from a 540 bp PCR product using
cDNA prepared from rat retinas (as described in the
qPCR section), and which was synthesised into a digoxi-
genin (DIG)-labelled riboprobe according to our previ-
ous publication [41]. The in situ hybridisation was
performed using our established protocol [51]; the Ccl3
riboprobe was hybridised on retinal cryosections over-
night at 55 °C and then washed in decreasing concentra-
tions of saline sodium citrate (pH 7.4) at 60 °C. The
bound probe was visualised with either NBT/BCIP or
HNNP/Fast-Red (Roche).
Statistical analysis
All graphing and statistical analysis was performed using
Prism 6 (GraphPad Software, CA, USA). A two-way
ANOVA with Tukey’s multiple comparison post-test or
an unpaired Student t test was utilised to determine the
statistical outcome; a P value of <0.05 was considered
statistically significant.
Results
Stability and localisation of NR58-3.14.3 in injected
retinas
Localisation and persistence of NR58-3.14.3 within the
retina was determined by intravitreal injections of
fluorescein-conjugated NR58-3.14.3 (Fig. 1). At 20 min
post-injection, levels of fluorescence increased dramatic-
ally in retinas injected with NR58-3.14.3-fluorescein,
compared to fluorescein-only- and non-injected controls
(P < 0.05, Fig. 1a). Fluorescence levels were maintained
at 3 h post-injection, though were reduced by approxi-
mately a third after 24 h—this was not significant however
compared to the 20 min post-injection group (P > 0.05).
After 7 days, fluorescence was still present in NR58-
3.14.3-fluorescein-injected retinas at levels significantly
higher than the fluorescein-only- and non-injected control
groups (P < 0.05).
At 20 min-post-injection, NR58-3.14.3-fluorescein was
distributed throughout the retina, spanning the ganglion
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cell layer (GCL) to the RPE (Fig. 1b). This distribution
was mostly unchanged after 3 h, although fluorescence
appeared more concentrated within the GCL, nerve fibre
layer (NFL), inner nuclear layer (INL), and RPE (Fig. 1c,
arrows). After 24 h incubation, fluorescence was local-
ised in intense clusters encompassing the NFL, retinal
vasculature, and RPE (Fig. 1d, arrows). This localisation
was maintained at 7 days post-injection (Fig. 1e, arrows),
while fluorescein-only controls showed little fluores-
cence at all (Fig. 1f ).
Tolerance of NR58-3.14.3 within the retinal environment
NR58-3.14.3 was initially injected into dim-reared ret-
inas to determine whether it induced any change in
photoreceptor death, retinal stress, or macrophages
alone (Fig. 2). At 24 h following intravitreal injection
with NR58-3.14.3, analyses showed no significant change
in the number of TUNEL+ photoreceptors (P > 0.05,
Fig. 2a) or in integrity of the retinal layers (Fig. 2c, d),
compared to control retinas; both parameters were con-
sistent with our previous measurements in control SD
retinas [44]. General retinal stress was assessed via im-
munohistochemistry for GFAP (Fig. 2g, h), an accepted
indicator of retinal pathology [52]. Immunoreactivity for
GFAP was confined to the GCL (arrows) in both NR58-
3.14.3- and PBS-injected retinas, consistent with a nor-
mal physiological retinal state [44, 52, 53]. Finally, there
was no change in the distribution of IBA1+ microglia/
macrophages in NR58-3.14.3-injected retinas compared
to PBS-injected controls (P > 0.05, Fig. 2b, e, f ). The
outer nuclear layer (ONL) and subretinal space was de-
void of macrophages in both groups (Fig. 2e, f, arrows),
while resident microglia/macrophages in the inner retina
showed no change in number or morphology.
Effect of NR58-3.14.3 on macrophage accumulation fol-
lowing light damage
The accumulation of macrophages within the outer ret-
ina (including the photoreceptor layer and subretinal
space) following NR58-3.14.3 injection was assessed
using IBA1 immunoreactivity (Fig. 3) to identify micro-
glia/macrophages [54, 55]. Immediately following light
damage (0 day recovery), we observed a substantial
incursion of IBA1+ cells into the outer retina of PBS-
injected controls (23 per retinal section, Fig. 3a, c, d
arrows). In animals injected with NR58-3.14.3, this accu-
mulation was substantially less at 6 per retinal section
(P < 0.05) (Fig. 3a, e).
In PBS-injected animals 7 days post-light damage, the
number of IBA1+ cells increased significantly through-
out the retina, particularly in the subretinal space
(Fig. 3a) where accumulations of swollen, amoeboid-like
macrophages were observed among the degenerating
photoreceptor segments (Fig. 3f, g arrows). In animals
injected with NR58-3.14.3, however, the number of IBA1
+ cells infiltrating the outer retina was significantly less
than in PBS controls (27 and 80 per retina respectively,
P < 0.05, Fig. 3a), and virtually no macrophages were
detected in the subretinal space (Fig. 3h). Conversely,
the numbers of IBA1+ cells in the inner retina was simi-
lar in NR58-3.14.3- and PBS-injected animals at both 0
and 7 days recovery (P > 0.05, Fig. 3b).
Change in photoreceptor integrity following NR58-3.14.3
injection and light damage
The effect of NR58-3.14.3 administration on photo-
receptor cell death following light-induced damage was
investigated using the TUNEL assay (Fig. 4). Exposure to
bright continuous light induced an increase in the num-
ber of TUNEL+ photoreceptors in both PBS- and NR58-
3.14.3-injected groups (Fig. 4a). However, the number of
TUNEL+ cells in animals injected with NR58-3.14.3 was
approximately half that in the PBS-injected control ani-
mals at 0 day recovery (235 and 419 per retinal section,
P < 0.05, Fig. 4a–c). The effect of NR58-3.14.3 was even
more pronounced during the chronic phase of degener-
ation at 7 days recovery, wherein the number of TUNEL+
photoreceptors was four times lower in NR58-3.14.3-
Table 1 TaqMan hydrolysis probes used for qPCR
Gene symbol Gene name Catalog number Entrez gene ID
Ccl2 Chemokine (C–C motif) ligand 2 Rn01456716_g1 24770
Ccl3 Chemokine (C–C motif) ligand 3 Rn00564660_m1 25542
Ccl4 Chemokine (C–C motif) ligand 4 Rn00587826_m1 116637
Ccl7 Chemokine (C–C motif) ligand 7 Rn01467286_m1 287561
IL-6 Interleukin 6 Rn01410330_m1 24498
IL-1B Interleukin 1β Rn00580432_m1 24494
TNF Tumour necrosis factor α Rn00562055_m1 24835
IL-12B Interleukin 12β Rn00575112_m1 64546
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Rn99999916_s1 24383
ACTB Actin, beta Rn00667869_m1 81822
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injected animals compared with the PBS controls (38 and
164 per retinal section, P < 0.05, Fig. 4a, d, e). In addition,
the cumulative effect of NR58-3.14.3 on the number of
surviving photoreceptors following light damage was de-
termined via measurements of ONL thickness. There was
no change in the number of photoreceptor rows at 0 day
recovery compared to PBS controls (P > 0.05, Fig. 4f). At
7 days recovery, however, there was an increased number
of photoreceptor rows in NR58-3.14.3 retinas compared
to those in PBS controls (P < 0.05, Fig. 4f–h).
Fig. 1 Stability and localisation of intravitreally injected NR58-3.14.3. a Levels of fluorescence readily increased in retinas injected with fluorescein-
conjugated NR58-3.14.3 after only 20 min and remained highly elevated after 3 h. Fluorescence was significantly lower at 7 days post-injection
(P < 0.05), but was still far higher than fluorescein-only- and non-injected controls (P < 0.05). b NR58-3.14.3-fluorescein (green, arrow) was present
throughout the retina at 20 min post-injection. c Fluorescence remained consistent in retinas after 3 h, though was more concentrated within
the GCL, NFL, INL, and RPE (arrows). d, e After 24 h and 7 days post-injection, fluorescence for NR58-3.14.3-fluorescein was markedly reduced but still
readily apparent around the NFL, retinal vasculature, and RPE (arrows). f Retinas injected with fluorescein-only showed only very faint background
fluorescence in comparison to NR58-3.14.3-fluorescein-injected animals (e). GCL ganglion cell layer, INL inner nuclear layer, NFL nerve fibre layer, ONL
outer nuclear layer, RPE retinal pigment epithelium. Scale bars represent 100 μm. NR58-3.14.3-fluorescein n= 3, fluorescein-only n= 3, non-injected n= 3
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Cytokine and chemokine expression following NR58-
3.14.3 injection and light damage
The expression of chemokines (Ccl2, Ccl3, Ccl4, Ccl7)
and cytokines (Il6, Il1b, TNFa, Il12) was assessed using
qPCR to determine the effect of NR58-3.14.3 on che-
mokine signalling (Fig. 5). These were selected based
on their up-regulation in our microarray analysis con-
ducted previously using the light damage model [41].
Expression levels of all genes were substantially up-
regulated immediately after bright light exposure
(0 day) in both PBS- and NR58-3.14.3-injected animals
(Fig. 5a, b). However, expression levels of Ccl3, Ccl4,
and Il6 were significantly less in NR58-3.14.3-injected
compared to PBS-injected animals (Fig. 5a, b; P < 0.05).
At 7 days post-light damage, expression levels of all cy-
tokines/chemokines assessed had dropped by approxi-
mately 80–90 % (Fig. 5c, d) and there was no difference
between expression levels in the two treatment groups
(P > 0.05).
Change in expression of inflammatory factors by
macrophages following NR58-3.14.3 injection and light
damage
Macrophages/microglia were FACS-sorted from retinal
suspensions for each treatment group on the basis of
CD11b immunoreactivity (Fig. 6a), which co-localises
with IBA1 [56–58]. CD11b was preferred over IBA1 as a
macrophage/microglial marker in this instance, because
the intracellular staining required for IBA1 would pre-
vent any downstream RNA analysis following FACS. We
first sought to confirm whether the CD11b+ macro-
phages expressed Ccl- and Cxcl- chemokine receptors
which correspond to the ligands up-regulated following
light damage [41], as well as in AMD [28]. Using stand-
ard PCR (Fig. 6b), CD11b+ macrophages/microglia from
both treatment groups were found to express Ccr1,
Ccr3, Ccr5, and Cxcr3 receptors.
To further explore the role of macrophages/microglia
in retinal inflammation, we compared the expression of
Fig. 2 Tolerance of NR58-3.14.3 within the retinal environment in relation to stress and macrophage recruitment. a Injection of dim-reared controls with
NR58-3.14.3 did not yield any change in TUNEL+ photoreceptors after 24 h incubation, compared to non-injected controls (P> 0.05). b NR58-3.14.3 alone
did not induce any recruitment of IBA1+ macrophages to the outer retina after 24 h incubation in dim-reared animals, and there was also no change in
the inner retinal population (P> 0.05). c, d The integrity of the ONL was unchanged in animals injected with NR58-3.14.3, compared to non-injected
controls. e, f The morphology of IBA1+ macrophages/microglia (green) was unaltered in NR58-3.14.3-treated retinas, and the ONL was devoid of any of
these cells (arrows) in both groups. g, h Immunoreactivity for stress marker GFAP was restricted to the GCL in both NR58-3.14.3 and non-injected groups
(arrows), consistent with a normal physiological state. GCL ganglion cell layer, IHC immunohistochemistry, INL inner nuclear layer, NFL nerve fibre layer, ONL
outer nuclear layer, RPE retinal pigment epithelium. Scale bars represent 100 μm. NR58-3.14.3 n= 3, non-injected n= 3
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Ccl3, Ccl4, and Il6 in isolated CD11b+ macrophages
from NR58-3.14.3-injected and PBS-injected groups
using qPCR. These were chosen due to their differential
expression in the whole-retina samples (shown in Fig. 5)
and the implicit roles of these genes in promoting
pathogenic macrophage activity [34, 59]. After light
damage, expression of Ccl3, Ccl4, and Il6 were signifi-
cantly decreased in CD11b+ cells from NR58-3.14.3-
injected retinas, compared to PBS controls (P < 0.05,
Fig. 6c). In situ hybridisation for Ccl3 mRNA showed
clusters of ramified microglia in the outer retina of PBS
controls (Fig. 7a, b arrows) following light damage,
which were also immunoreactive for IBA1 (Fig. 7e, f
arrows). Ccl3-expressing macrophages were far less
numerous in retinas from NR58-3.14.3-injected animals
(Fig. 7c, d arrows).
Discussion
The findings of the current study demonstrate the effi-
ciency of the broad-spectrum chemokine inhibitor
NR58-3.14.3 in modulating the pathogenic activity of
macrophages/microglia and ameliorating photoreceptor
death, in a model of photo-oxidative damage and outer
retinal inflammation. First, our data demonstrate that
the intravitreal delivery of NR58-3.14.3 is tolerated
within the retinal environment, and its persistence in the
retina provides for a generous window of activity. Sec-
ond, we show that injection of NR58-3.14.3 suppresses
Fig. 3 Macrophage/microglia recruitment to the outer retina following injection of NR58-3.14.3 and light damage. a, b At 0 day post-LD, there
was a substantial incursion of IBA1+ cells and their ramified processes into the outer retina of PBS-injected controls, which was substantially lower
in animals injected with NR58-3.14.3 (P < 0.05). During the chronic phase of degeneration at 7 days post-LD, the number of IBA1+ cells was further
increased in the outer retina, although animals injected with NR58-3.14.3 had far fewer IBA1+ cells than in PBS controls (P < 0.05). For the inner
retinal counts of IBA1+ macrophages/microglia, there was no change at either 0 or 7 days recovery for both treatment groups (P > 0.05). c–e
IBA1+ cells invaded ONL with their extended processes in PBS-injected animals at 0 day (c, d, arrows), which was not apparent in the NR58-3.14.3
group (e). f–h Accumulations subretinal IBA1+ macrophages were observed in PBS-injected animals at 7 days (f, g, arrows), while the subretinal
space was nearly devoid of these cells in NR-injected retinas. GCL ganglion cell layer, IHC immunohistochemistry, INL inner nuclear layer, NFL nerve fibre
layer, ONL outer nuclear layer, RPE retinal pigment epithelium. c–h Scale bars represent 100 μm and d, g 25 μm. N = 11 per group at 0 and 7 days
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the chronic accumulation of macrophages/microglia
within the photoreceptor layer and subretinal space fol-
lowing damage. Third, NR58-3.14.3-treated macrophages
demonstrated reduced pathogenic activation, indicated
by decreased expression of Ccl3, Ccl4, and Il6. Finally,
we show that photoreceptor degeneration is reduced
across the time course of damage in retinas injected with
NR58-3.14.3, which is accompanied by an increase in
photoreceptor survival at the site of focal and progres-
sive atrophy.
NR58-3.14.3 is thought to exert its inhibitory effect on
Ccl- and Cxcl- families though disruption of intracellular
signal transduction, which effectively renders leukocytes
blind to directional cues provided by Ccl- and Cxcl- li-
gands [60, 61]. This broad suppression is desirable, as the
blockade of singular chemokine ligands, such as Ccl2, can
induce compensatory increases in the expression other
chemokines which exacerbate retinal inflammation and
degeneration [34, 36]. Up-regulation of Ccl2, Cxcl1,
Cxcl10, and Cxcl11 are present in all forms of AMD [28],
and the Ccl2/Ccr2 axis is implicated in the pathogenic ac-
cumulation of macrophages to the outer retina in models
that feature aspects of either CNV or geographic atrophy,
such as light damage [16, 31–35]. Increases in ocular Ccl-
and Cxcl- chemokines are also found in individuals
affected by retinal detachment [62, 63], uveitis [64], glau-
coma [65], diabetic retinopathy, and retinitis pigmentosa
[66], while blockade of Ccl2 signalling has proven benefi-
cial in thwarting macrophage aggregation and cell death
in experimental retinal detachment, diabetic retinopathy
[23], and retinitis pigmentosa [67]. While the light damage
paradigm does not model features of CNV or
degenerations such as retinal detachment, our findings
allude to the potential of BSCIs in targeting a broad
swathe of chemokine activity across a spectrum of retinal
degenerations.
Fig. 4 Change in photoreceptor integrity following injection of NR58-3.14.3 and light damage. a At 0 day post-LD, animals injected with NR58-3.14.3
had approximately half the number of TUNEL+ cells per retina compared to PBS-injected controls (P < 0.05). After 7 days post-LD, where chronic retinal
degeneration is most apparent, the number of TUNEL+ photoreceptors was roughly three times lower in animals injected with NR58-3.14.3 than in
the PBS controls (P < 0.05). b–e Representative TUNEL images showcase the reduction in TUNEL+ photoreceptors in NR58-3.14.3-injected retinas at
both 0 (c) and 7 (e) days post-LD, compared to PBS controls (b, d). f At 0 day post-LD, there was no change in the number of rows of photoreceptor
nuclei in NR58-3.14.3-injected retinas compared to PBS controls (P > 0.05). However, at 7 days post-LD, animals injected with NR58-3.14.3 had a larger
number of remaining photoreceptor rows than PBS controls (P < 0.05). g, h Representative ONL images demonstrate this reduction of photoreceptor
loss in NR58-3.14.3-injected retinas compared to PBS controls at 7 days post-LD. INL inner nuclear layer, ONL outer nuclear layer. b–e Scale bars represent
100 μm and g–j 50 μm. N= 10–11 per group at 0 day, N= 12 per group at 7 days
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To our knowledge, this is the first study to examine
the potential of BSCIs as a potential therapeutic agent in
retinal disease. The findings from our study are consist-
ent with previous investigations using NR58-3.14.3 in
inflammatory models ranging from atherosclerotic pla-
ques to obliterative bronchiolitis, wherein an inhibition
of macrophage accumulation and amelioration of tissue
damage were observed [61, 68, 69]. Our own data show
that intravitreal NR58-3.14.3 reduces the accumulation
of macrophages within the outer retina, including ONL
and subretinal space. The proportion of these subretinal
macrophages that are either resident microglia or re-
cruited bone-marrow-derived monocytes is unclear, al-
though the effect of intravitreal NR58-3.14.3 on these
subpopulations is beyond the scope of this study. Never-
theless, we speculate that intravitreal NR58-3.14.3 could
impact the infiltration of both subpopulations to the
subretinal space, despite the local nature of its adminis-
tration. This is suggested by the localisation fluorescein-
NR58-3.14.3 within the retinal vasculature, where blood
borne monocytes are known to recruit into the retina
following light-induced injury [36].
Our data indicate that NR58-3.14.3 modulates the tran-
scriptional phenotype of macrophages following light
damage. The expression of Ccl3, Ccl4, and Il6 were all
down-regulated in macrophages exposed to NR58-3.14.3
and are consistent with the down-regulation of Il6 observed
in experimental obliterative bronchiolitis following adminis-
tration of NR58-3.14.3 [39]. Ccl3, Ccl4, and Il6 are markers
of M1 polarisation, which is typically associated with
deleterious pro-inflammatory responses [70]. Although
macrophage polarisation is considered a simplification
of extremes which form part of a phenotypic spectrum,
the suppression of these genes within the macrophage
population in NR58-3.14.3-injected retinas do point to-
ward a lower inflammatory state among these cells as a
result. How NR58-3.14.3 elicits this transcriptional
change is unclear, though we speculate it may occur via
its inhibition of macrophage chemotaxis to the outer
retina, wherein emergent photoreceptor death may
stimulate up-regulation of cytokines such as Ccl3, Ccl4,
and Il6. This is supported by our in situ hybridisation
data, wherein Ccl4 mRNA is expressed only in macro-
phages that have migrated to the outer retina.
Several lines of evidence suggest that Ccl3, Ccl4, and
Il6 are important mediators of pathogenic activity by
macrophages in retinal degeneration, which may account
for the neuroprotective action of NR58-3.14.3. Increased
levels of Il6 are associated with the incidence and pro-
gression of AMD, and the cytokine is considered a
Fig. 5 Expression of chemokines (a, c) and cytokines (b, d) in whole retinas following injection of NR58-3.14.3 and light damage. a, b All genes
assessed exhibited significant up-regulation at 0 day post-LD in both treatment groups. However, Ccl3, Ccl4, and Il6 had significantly lower expression
(P < 0.05) in retinas injected with NR58-3.14.3 compared to PBS controls. c, d By 7 days post-LD, up-regulation of all genes assessed was only 10–20 %
of that observed at 0 day, with no difference between NR58-3.14.3- and PBS-injected groups (P> 0.05). 0 day N= 11–12 per group, 7 days N= 5 per group
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Fig. 7 In situ hybridisation for Ccl3 mRNA following NR58-3.14.3 injections and light damage. a, b At 0 day LD recovery in PBS-injected retinas,
there was staining for Ccl3 mRNA (purple) in among clusters of irregularly shaped nuclei traversing the ONL (arrows). c, d Retinas injected NR58-3.14.3,
conversely, displayed very few Ccl3-expressing nuclei. e, f Ccl3-expressing nuclei (red, arrow) correlated strongly with immunofluorescence for IBA1+
macrophages/microglia (green, arrow). IHC immunohistochemistry, ISH in situ hybridisation, ONL outer nuclear layer, OS outer segments. Scale bars
represent 50 μm
Fig. 6 Effect of NR58-3.14.3 on the pathogenic phenotype of the retinal macrophage population following light damage. a Representative FACS
plots, with gating strategies for the isolation of CD11b+ macrophages/microglia. Gating methodology was applied equally for all samples. b Representative
images of PCR products via electrophoresis for chemokine receptors Ccr1, Ccr2, Ccr5, and Cxcr3, in samples of CD11b-sorted cells. Receptor expression
was observed in both NR58-3.14.3 and PBS CD11b isolates. c Following exposure to LD, expression of Ccl3, Ccl4, and Il6 were all decreased in CD11b+
macrophages isolated from NR58-3.14.3-injected retinas, compared to those from PBS-injected retinas (P < 0.05). N = 5 per group at 0 day
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potential therapeutic target [71–73]. A pathogenic role of
Il6 is more recently highlighted by Levy and colleagues,
who show that accumulation of the AMD biomarker apo-
lipoprotein E (APOE) in subretinal macrophages up-
regulates their expression of Il6, which in turn promotes
their increased survival and induction of retinal pathology
in light-damaged Cx3cr1−/− mice [59]. Additionally, a
deleterious role of Il6 has been characterised in experi-
mental ocular toxoplasmosis via antibody neutralisation,
which considerably improved retinal morphology com-
pared to controls [74].
Ccl3 is implicated in animal models of AMD/Star-
gardt disease (Abca4−/−Rdh8−/−), retinitis pigmentosa
(Mertk−/−) [34], and oxygen-induced retinopathy
[75]. Ccl3 was expressed by macrophages/microglia as
shown by Kohno and colleagues—consistent with our
current investigation—and its ablation reduced the ex-
tent of photoreceptor degeneration in both aged
Abca4−/−Rdh8−/− mice and young Mertk−/− mice
[34]. In experimental oxygen-induced retinopathy,
mice were treated with the combination therapy of
Ccl3- and Ccl2-neutralising antibodies, rather than a
singular therapy. Regardless, the neovascular path-
ology was reduced by 30 % in these animals [75]. The
precise role of Ccl4 in retinal degeneration has yet to be
examined, although protein levels are increased in the
aqueous humour of AMD patients [76], and its expression
is up-regulated concomitantly with emergence of retinal
degeneration in experimental light damage [41], diabetic
retinopathy, and Abca4−/−Rdh8−/− and Mertk−/−
mice [34]. Moreover, ablation of Ccl3 induced compen-
satory increases in Ccl4 expression in light-damaged
Abca4−/−Rdh8−/− mice, which was postulated to con-
tribute to the increased pathology observed in this
paradigm (rather than the age paradigm where there
was protection).
We speculate that NR58-3.14.3 may also confer retinal
protection by inhibiting other macrophage processes,
such as aberrant phagocytosis. This phenomenon has
been recently demonstrated in the rd10 model of retin-
itis pigmentosa, in which infiltrating microglial cells
were found to exacerbate cell death by phagocytosing
non-apoptotic photoreceptors [77]. In suppressing the
infiltration of macrophages within the outer retina,
NR58-3.14.3 may also reduce the erratic phagocytosis of
photoreceptors by activated macrophages. This may be a
contributing factor to the increases in ONL thickness in
NR58-3.14.3-injected retinas, although additional inves-
tigations are required to firmly establish this in the
future.
Conclusions
Our findings showcase the efficacy of BSCIs such as NR58-
3.14.3 in modulating macrophage/microglia responses in
retinal degeneration. NR58-3.14.3 ameliorated the chronic
aggregation of subretinal macrophages in light-induced
subretinal inflammation and suppressed their potentiation
of Il6, Ccl3, and Ccl4 signalling. As with all current models,
light damage does not encompass every aspect of AMD
pathology; nevertheless, our findings have implications for
the treatment of inflammation in the disease. Chemokines
are associated with the aggregation of subretinal macro-
phages in AMD, while expression of Il6, Ccl3, and Ccl4 are
implicated in augmenting their survival and pathogenicity
within the subretinal space. Together, these experiments
offer proof-of-principle for the potential of BSCIs as thera-
peutic agents in targeting subretinal inflammation in dis-
eases such as AMD.
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